Pregled bibliografske jedinice broj: 897113
Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis
Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis // International journal of antimicrobial agents, 24 (2004), 2; 188-191 doi:10.1016/j.ijantimicag.2004.03.014 (recenziran, članak, stručni)
CROSBI ID: 897113 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis
Autori
Škerk, Višnja ; Krhen, Ivan ; Lisić, Miroslav ; Begovac, Josip ; Roglić, Srđan ; Škerk, Vedrana ; Ljubin Sternak, Sunčanica ; Banaszak, Artur ; Strugar-Šuica, Jadranka ; Vuković, Jacinta
Izvornik
International journal of antimicrobial agents (0924-8579) 24
(2004), 2;
188-191
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
chronic prostatitis ; Chlamydia trachomatis ; azithromycin ; doxycycline
Sažetak
The study included 125 adult patients (> 18years of age) who had symptoms of chronic prostatitis and proven presence of Chlamydia trachomatis. The presence of C. trachomatis was confirmed in expressed prostatic secretion or in voided bladder urine collected immediately after prostatic massage by a DNA/RNA hybridization method and/or by isolation on McCoy culture and then by immunofluorescent typing with monoclonal antibodies. The patients were randomized in the ratio 2/1 ; azithromycin/doxycycline, to receive a total of 4.0 g azithromycin over 4 weeks, given as a single dose of 1 x 1000 mg weekly for 4 weeks or doxycycline 100 mg b.i.d. for 28 days. Patients' sexual partners were treated at the same time. Clinical and bacteriological efficacy was evaluated 4-6 weeks after the end of therapy. In the group of patients with chlamydial infection of the prostate, there was no significant difference between the eradication rates (azithromycin 65/82, doxycycline 33/43 ; P = 0.82) and the clinical cure rates (azithromycin 56/82, doxycycline 30/43 ; P = 0.94) of the two antimicrobials.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Hrvatski zavod za javno zdravstvo,
Pliva-Istraživački institut,
Medicinski fakultet, Zagreb,
Klinika za infektivne bolesti "Dr Fran Mihaljević",
Klinički bolnički centar Zagreb
Profili:
Sunčanica Ljubin Sternak
(autor)
Vedrana Škerk
(autor)
Josip Begovac
(autor)
Višnja Škerk
(autor)
Miroslav Lisić
(autor)
Srđan Roglić
(autor)
Ivan Krhen
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE